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Abstract
Little is known about the genetic factors modulating the progression of Huntington’s dis-
ease (HD). Dopamine levels are affected in HD and modulate executive functions, the main
cognitive disorder of HD. We investigated whether the Val158Met polymorphism of the cate-
chol-O-methyltransferase (COMT) gene, which influences dopamine (DA) degradation,
affects clinical progression in HD. We carried out a prospective longitudinal multicenter
study from 1994 to 2011, on 438 HD gene carriers at different stages of the disease (34
pre-manifest; 172 stage 1; 130 stage 2; 80 stage 3; 17 stage 4; and 5 stage 5), according to
Total Functional Capacity (TFC) score. We used the Unified Huntington’s Disease Rating
Scale to evaluate motor, cognitive, behavioral and functional decline. We genotyped partici-
pants for COMT polymorphism (107 Met-homozygous, 114 Val-homozygous and 217 het-
erozygous). 367 controls of similar ancestry were also genotyped. We compared clinical
progression, on each domain, between groups of COMT polymorphisms, using latent-class
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mixed models accounting for disease duration and number of CAG (cytosine adenine gua-
nine) repeats. We show that HD gene carriers with fewer CAG repeats and with the Val
allele in COMT polymorphism displayed slower cognitive decline. The rate of cognitive
decline was greater for Met/Met homozygotes, which displayed a better maintenance of
cognitive capacity in earlier stages of the disease, but had a worse performance than Val
allele carriers later on. COMT polymorphism did not significantly impact functional and
behavioral performance. Since COMT polymorphism influences progression in HD, it could
be used for stratification in future clinical trials. Moreover, DA treatments based on the spe-
cific COMT polymorphism and adapted according to disease duration could potentially
slow HD progression.
Introduction
Huntington’s disease (HD) is an autosomal dominant inherited neurodegenerative disease
caused by increased number of CAG (cytosine adenine guanine) repeats in the Huntingtin
(Htt) gene on chromosome 4 [1]. It primarily affects the striatum and manifests as progressive
motor, behavioral and cognitive disturbances, leading to death about 15 to 20 years after onset.
There is currently no effective course-modifying treatment.
Phenotypic expression differs considerably between patients. Age at onset varies and few of
the underlying genetic factors for this variability have been identified [2]. The size of the num-
ber of CAG repeats in the mutated Htt (mHtt) gene is inversely related to age at onset of HD
patients, but accounts for only 40 to 70% of its variance [3]. The implication of other genes in
HD such as the PPARGC1A, GRIK2,APOE and BDNF genes, has been shown, but their impact
was not replicated in subsequent studies [4, 5, 6]. The factors influencing disease progression
remain to be identified [7]. Higher number of CAG repeats in themHtt gene is associated with
faster motor, cognitive, and functional decline [8]. The influence of the number of CAG repeats
in the normalHtt allele remains uncertain, either on age at onset or disease progression [3, 9].
Here, in addition to results provided by genome wide associationmapping conducted on
the motor onset [10], we conduct an a priori study on the catechol-O-methyltransferase
(COMT) to assess its impact on HD evolution [11]. COMTmay play a role in HD because it
degrades catecholamines, such as dopamine (DA). Medium-sized striatal spiny GABAergic
neurons bearing dopaminergic receptors (D1 and D2) are preferentially affected in HD [12].
The density of these receptors in the striatum decreases [13] along with DA and GABA con-
centrations in HD patients. DA receptors loss correlates with disease progression in mouse HD
models [14]. Furthermore, DA receptors dysfunction is correlated with cognitive impairment
in HD gene carriers [15]. In the normal population, the presence of a Valine instead of a Methi-
onine in position 158 (Val158Met) on the COMT gene on chromosome 22 increasesCOMT
activity to levels 38% higher for the Val/Val genotype than for the Met/Met genotype [16],
resulting in lower DA levels in Val/Val homozygotes. COMT polymorphism essentially affects
DA levels in the prefrontal cortex (PFC), whereas striatal DA level is regulated principally by
the DA transporter (DAT). However, there is an interaction betweenDAT and COMT genes in
the regulation of DA level in the fronto-striatal system [17]. Indeed,COMT polymorphism
influences the severity of cognitive and behavioral symptoms in other diseases affecting subcor-
tical DA regulation, such as Parkinson’s disease [18, 19] and schizophrenia [20], and is predic-
tive of disease progression and psychosis in 22q11.2 deletion syndrome [21], another disease
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related to striatal dysfunction. Additionally, in early stages of Huntington’s disease the PFC
function appears to have an important role in compensation of cognitive impairment [22].
In HD, COMT polymorphism has no influence on motor onset [4], but its effect in behav-
ioral, cognitive and functional domains has not been investigated except in a very recent study.
In a cross-sectional study of 121 HD patients, Vinther-Jensen et al [23] found that COMT and
MAOA polymorphismwere associated with behavioral symptoms or cognitive impairment,
respectively. The link between polymorphisms in genes involved in the dopaminergic pathway
and the behavioral and cognitive symptoms highlights the role of dopamine regulation in HD
symptomatology. However, patients were not assessed longitudinally, and the impact of
COMT polymorphism in disease progression remains unexplored.
The cognitive effects of COMT polymorphism in various diseases and in healthy popula-
tions have repeatedly been reported to be specific to executive functions (see [24, 25] for
reviews), and executive function defects are the hallmark of cognitive dysfunction in HD. Fur-
thermore, even at low doses, DA aggravatesmHtt toxicity in striatal neuron cultures [26] and
increases behavioral and motor deficits in YAC128 mice [27], a transgenic model of HD. Thus,
COMT polymorphismmay affect the progression of HD.
In this study, we investigated the impact of COMT polymorphism on HD progression on
cognitive, motor, behavioral and functional decline, in a longitudinal long-term prospective
study.
Material and Methods
Participants
We report a longitudinal prospective long-term study of 438 HD gene carriers from the Predic-
tive Biomarkers for Huntington’s disease protocol (NCT01412125), which was approved by
the ethics committee of Henri Mondor Hospital (Créteil, France) in accordance with EU and
French bioethics laws. All HD gene carriers gave written informed consent. They were hetero-
zygous for theHtt gene (> 36 CAG repeats inmHtt) and aware of their genetic status. They
had no other neurological conditions or long-term experimental treatment (e.g. cell
transplantation).
Data were collected from 1994 to 2011, at eight centers from the French SpeakingHunting-
ton’s Disease Group (Angers: 24%, Bordeaux: 7%, Créteil: 34%, Lille: 4%, Lyon: 1%, Marseille:
12%, Paris: 11%, Strasbourg: 7%), and centralized at the National Reference Centre for Hun-
tington’s disease in Créteil.
Blood samples were centralized at the DNA bank of Pitié-SalpêtrièreHospital. The number
of CAG repeats was routinely determined [28]. The rs4680 (COMTVal158Met) polymorphism
was genotyped by PCR with appropriate primers [29]. We investigated the distribution of
COMT genotypes in the general population, by genotyping 367 independent controls with sim-
ilar ancestry with the same technique.
Clinical assessment
HD gene carriers were followed up with the Unified Huntington’s Disease Rating Scale
(UHDRS) [30], which combines motor, functional, behavioral and cognitive assessments.
Motor domain was assessed using the Total Motor Score (TMS, range: 0 to 124). Functional
domain was assessed using the Total Functional Capacity scale (TFC, range: 13 to 0), Func-
tional Assessment Scale (FAS, range: 25 to 50) and Independence Scale (IS, range: 100 to 0).
Behavioral domain was assessed using the psychiatric part of the UHDRS (range: 0 to 88). Cog-
nitive domain was assessed using the Stroop Test (color naming: Stroop C, word reading:
StroopW, and color-word interference: Stroop C/W), Symbol Digit Modality Test (SDMT),
COMT Polymorphism in Huntington’s Disease
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and letter fluency (for P, R and V in French). For letter fluency, testing at two minutes appears
to be more sensitive than testing at one minute [31]. The French version used in this study
includes both measurements. Higher scores in IS, FAS and TMS indicate greater impairment.
For all other tasks, higher scores indicate lower impairment.
The first evaluation corresponding to the entrance in the study (first visit) occurred before
onset (pre-manifest) in some individuals and at various times after onset in others, such that
the sample encompassed the entire spectrumof HD progression (first visit: 8% pre-manifest
gene carriers; 39% patients at Stage 1; 30% Stage 2; 18% Stage 3; 4% stage 4; and 1% Stage 5).
Pre-manifest gene carriers were defined as having a TMS below or equal to 5 [32], and a TFC
score of 13. The visits were performed annually, with few exceptions, with a mean inter-visit
delay of 1.2 years (SD = 0.4). The mean number of visits per HD gene carriers was 5.0
(SD = 3.2; range: 1 to 19 visits). Thirty-twoHD gene carriers were seen only once. Data were
recorded for 2185 visits. The mean duration of follow-up was 4.3 years for the whole cohort
(SD = 3.0; range: 0 to 15.5 years), and 4.8 years (SD = 2.9) years when excluding patients
assessed once.
The date at onset was available for 86.53% of the HD gene carriers. It corresponds to the
appearance of the first symptoms, and it was determined (observed)by the clinician (93.14%),
or, if missing, by the family (5.28%), or, if missing that as well, by the participant (1.58%).
Statistical analyses
Demographics and characteristicsof COMT polymorphismgroups at the first visit.
The χ2 goodness-of-fit test was computed to compare the distribution of COMT genotypes in
the 438 HD gene carriers and in the control group. Stability of the genotype frequencywas
assessed through the Hardy-Weinberg test in controls.
We assessed whether baseline characteristics of HD gene carriers were similar in the differ-
ent COMT polymorphism samples (Met/Met, Val/Val and Met/Val), by first assessing the dif-
ferences between groups for each score of the UHDRS at the first visit. Demographic data and
clinical characteristics of the sample (N = 438) at the first visit were compared between groups,
with a Pearson’s χ2 tests for qualitative variables and a one-way ANOVA for quantitative vari-
ables. For variables with significant difference between groups, student’s t-tests (or Welch’s
tests in cases of unequal variances) were performedwith Bonferroni correction for multiple
pairwise comparisons (see S1 Table for the same comparisons in the subgroup included in the
longitudinal analysis).
Number of CAG repeats and age at onset. We first assessed the impact of the number of
CAG repeats on age at onset in the 379 HD gene carriers with these available data. We used a
linear regression model, with age at onset as the dependent variable and the number of CAG
repeats as an independent variable. The R2 value provided by the model is an estimate of the
proportion of the variability of the age at onset explained by the number CAG repeats.
We also calculated an expected age at onset according to the Langbehn et al. model [33],
derived from the number of CAG repeats using the formula: expected age = (21.54 + exp
(9.556–0.146CAG)). We evaluated the agreement between this expected age at onset and the
age at onset provided in our database by calculating the intraclass correlation coefficient (ICC),
a measure for concordance. The ICC was obtained by a two-way mixed effectmodel [34].
Longitudinal analysis of disease progression. The longitudinal analysis was conducted
on 1912 visits of the 350 HD gene carriers with at least two visits and for which the date of
onset was known.
We compared progression over time between groups, by calculating the overall change in
motor, functional, behavioral and cognitive domains per year since the date of onset. Domains
COMT Polymorphism in Huntington’s Disease
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are not observable per se but are modeled by a latent variable reflected by observedperfor-
mances at each task. We performed four latent-class mixed models [35], one per domain,
where each model combines: (i) a linear mixed model to explain latent domain according to
covariates, and (ii) beta transformations which link observedperformances at each task to
latent domain (Fig 1). Similarly to classical linear mixedmodels, the latent-class mixed model
allows integrating data fromHD gene carriers with unequal duration of follow-up and intro-
ducing a subject-specific intercept by random effects to account for within-unit correlation for
outcome and between-subject variability [36]. These models take into account all observations
for each patient, without listwise deletion.Moreover, the use of beta transformations allows
taking into account the ceiling and floor effects of UHDRS tasks.
Parameters of linear mixed model and beta transformations are estimated simultaneously
using maximum likelihoodmethod and Monte-Carlo integration. The disease duration (time
since onset), COMT polymorphism, number of CAG repeats inmHtt, interaction between dis-
ease duration and the number of CAG repeats, interaction between disease duration and
COMT polymorphism, gender [37] and education level were retained as covariates. For COMT
polymorphism, included in the model as a categorical covariate, Met/Met was the reference
group, allowing the comparison betweenMet/Met and Val/Val genotypes and betweenMet/
Met and Met/Val genotypes.We compared Met/Val and Val/Val genotypes by recomputing
the models withMet/Val genotype as the reference group. All P-values were adjusted with Bon-
ferroni correction in two steps: one within the COMT polymorphism groups comparison and
one for multiple comparisons across domains. Based on Akaike’s information criterion and
Bayesian information criterion [38], number of CAG repeats in the normalHtt allele and
CAG-COMT interaction did not improve model fit, thus they were removed from the final
model. Similarly, accounting for the age at onset rather than for the number of CAG repeats
did not improve model fit.
To assess the robustness of the results, a sensitivity analysis was performed excluding outli-
ers, on the basis of the number of CAG repeats and of the distribution of dates of visits in our
cohort (see S1 Fig and S2 Fig). The sensitivity analysis included HD gene carriers with a num-
ber of CAG repeats between 39 and 49 that were followed in the 20 years after disease onset.
Analyses were conducted with R 2.3 software (http://www.r-project.org/). The R package
lcmmwas used to perform the longitudinal analysis. All tests were two-tailed. Values of
P< 0.05 were considered significant.
Results
Demographics and characteristics of COMT polymorphism groups at
the first visit
The χ2 goodness-of-fit test confirms that the distribution of COMT genotypes is similar in HD
gene carriers and the control group (P = 0.15) (see Table 1). The genotype frequencies remain
constant from generation to generation (Hardy-Weinberg P = 0.13).
Demographic and clinical data of HD gene carriers for the first visit are displayed in
Table 2. Baseline demographic and clinical characteristics are similar for all COMT polymor-
phisms (one-way ANOVA, P> 0.05) except that HD gene carriers with the Met/Val genotype
have a lower educational level than those with the Val/Val (pairwise comparison, corrected
P = 0.01) or Met/Met (pairwise comparison, correctedP = 0.01) genotypes. Descriptive analysis
of HD gene carriers included in the longitudinal analysis is provided on S1 Table. COMT poly-
morphism does not impact age at onset.
Number of CAG repeats and age at onset. The number of CAG repeats explains 49.61%
of the variability of age at onset (β coefficient = -2.07 (SE = 0.11), P< 0.001).
COMT Polymorphism in Huntington’s Disease
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The ICCmeasuring agreement between expected age at onset by formula (1) and age at
onset provided in the database is high for the whole cohort (0.71: [95% CI 0.65–0.76],
P< 0.0001) and in each COMT group (Met/Met ICC = 0.75 [95% CI 0.64–0.83], P< 0.0001,
Met/Val ICC = 0.70 [95% CI 0.62–0.77], P< 0.0001 and Val/Val ICC = 0.66 [95% CI: 0.54–
0.76], P< 0.0001) (Fig 2).
Fig 1. Structure of the latent class mixed models. Red dashed line includes variables used for the linear mixed
model part. Blue dashed line includes variables used for the beta transformation. Latent domain represents the
non-observable motor, behavioral, functional or cognitive domains. Observed task performances are those
measured using the UHDRS. The latent motor process was modeled using the TMS; the latent behavioral process
was modeled using the UHDRS behavioral score; the latent functional process was modeled using the FAS and IS
scores; The latent cognitive process was modeled using letter fluency at 1 minute, letter fluency at 2 minutes,
SDMT, Stroop Color, Stroop Word and Stroop Word/Color interference.
doi:10.1371/journal.pone.0161106.g001
COMT Polymorphism in Huntington’s Disease
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Longitudinal analysis of disease progression
Table 3 displays the modeling parameters of the linear mixedmodels corresponding to the dis-
ease evolution within the four domains: motor, behavior, functional and cognitive. After cor-
recting P-values, there is no effect of COMT polymorphism or the number of CAG repeats on
latent processes at time 0 (estimated onset). A higher education level is correlated with higher
performance in cognitive and functional domains. Gender influences the disease evolution.
Men were behaviorally less impaired than women at onset. In addition, men declinemore
slowly than women in both the motor and cognitive domains. For all COMT polymorphism,
Table 1. Distribution of the COMT genotypes in HD gene carriers and control groups.
Met/Met Met/Val Val/Val
Controls N (%) 70 (19.1) 202 (55.0) 95 (25.9)
HD gene carriers N (%) 107 (24.4) 217 (49.6) 114 (26.0)
HD: Huntington’s disease; Met: Methionine; Val: Valine
doi:10.1371/journal.pone.0161106.t001
Table 2. Demographic characteristics and performance of HD gene carriers.
N Met/Met Met/Val Val/Val P*
Age (yrs) 438 46.1 (12.8) 49.5 (12.1) 47.9 (11.2) Ns
Sex (% men) 438 55.1 47.0 52.6 Ns
Age at onset (yrs) 379 41.9 (11.6) 45.3 (11.5) 43.6 (9.7) Ns
Educational level (yrs in education) 435 12.3 (3.4) 11.2 (2.9) 12.2 (3.3) 0.0012
BMI 382 22.6 (3.7) 22.7 (3.6) 22.1 (3.5) Ns
CAG repeats mHtt 438 45.3 (4.5) 44.5 (3.6) 44.6 (3.1) Ns
CAG repeats Htt 438 18.3 (2.8) 18.9 (4.1) 18.9 (3.9) Ns
Antipsychotic use (%) 438 75.7 73.3 72.8 Ns
Antidepressant use (%) 438 28.0 27.6 28.1 Ns
Benzodiazepine use (%) 438 24.3 23.0 14.0 Ns
UHDRS
TMS 421 30.6 (19.7) 32.3 (22.0) 35.9 (23.3) Ns
Behavior 402 17.8 (13.4) 17.1 (11.0) 16.3 (12.0) Ns
FAS 424 29.4 (5.3) 30.0 (5.9) 30.7 (6.0) Ns
IS 425 84.3 (15.2) 83.0 (16.7) 81.1 (16.4) Ns
TFC 438 9.4 (3.4) 9.3 (3.4) 8.8 (3.6) Ns
L Fluency 1’ 340 22.7 (12.9) 20.0 (12.6) 19.7 (13.1) Ns
L Fluency 2’ 350 33.3 (21.4) 28.8 (19.9) 28.2 (20.6) Ns
Stroop W 364 64.4 (24.9) 61.9 (23.3) 65.4 (27.5) Ns
Stroop C 365 47.8 (20.6) 43.8 (17.1) 46.7 (20.7) Ns
Stroop W/C 362 25.8 (14.3) 23.6 (12.8) 23.6 (15.4) Ns
SDMT 314 26.6 (16.6) 24.1 (15.2) 25.1 (17.3) Ns
HD: Huntington’s disease; BMI: body mass index; CAG repeats refers to the number of CAGs in the mutated (mHtt) and non-mutated (normal Htt) alleles of
the Huntingtin gene; UHDRS: Unified Huntington’s Disease Rating Scale; TMS: Total Motor Score; FAS: Functional Assessment Scale; IS: Independence
Scale; TFC: Total Functional Capacity; Letter fluency (L Fluency) was tested with PRV letters (French norms) at 1 minute (1’) and 2 minutes (2’); Stroop C:
Color; W: Word; W/C: Word/Color (interference score); SDMT: Symbol Digit Modalities Test. N: Number of patients for each variable where the data were
available. Quantitative variables are presented as means, with the standard deviation in brackets, and qualitative variables are presented as frequency
counts. Medication use is expressed as a percentage.
*Non corrected P-values; Chi-squared test for qualitative variables and one-way ANOVA for quantitative data; Ns: not significant.
doi:10.1371/journal.pone.0161106.t002
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performance declined over time for the motor, cognitive, and functional domains but not for
behavior (see Fig 3). Higher number of CAG repeats is associated with a faster decline for
motor, cognitive and functional domains. Met/Met HD gene carriers decline faster than Val/
Val and Met/Val HD gene carriers in the cognitive domain. Met/Val HD gene carriers decline
faster than Val/Val HD gene carriers in the motor domain while not differing from the Met/
Met group. At age at onset and over the 10 years following disease onset, Met/Met HD gene
carriers outperformMet/Val and Val/Val HD gene carriers in the cognitive domain. However,
since they decline faster they subsequently perform less well than the other HD gene carriers
(Fig 3 and Fig 4). The intersection of the progression curves for the Met/Met and Met/Val
groups is estimated at 7.2 years for the cognitive domain. The intersection of the Met/Met and
Val/Val curves is estimated at 10.9 years for the cognitive domain. The intersection of the Met/
Val and Val/Val curves is estimated at 11.0 years for the motor domain.
Fig 2. Concordance between predicted and real age at onset. Each point represents an individual patient. The
observed age at onset is the one provided in the database. The predicted age at onset is the one calculated by the
formula 21.54 + exp(9.556–0.146 x CAG). The gray line is the first bisector corresponding to the line of
predicted = observed. The closeness of the points to the gray line indicates the extent to which predicted age at
onset matches real age at onset. If predicted age at onset is greater than the observed age at onset, the points are
located above the gray line. By contrast, if the predicted age at onset is below the real age at onset, the points are
located below the gray line.
doi:10.1371/journal.pone.0161106.g002
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Fig 4 shows that for most tasks, the fit of disease is linear only for the first 15 years, display-
ing a floor effect after that point. Beta link functions between performance at each task and
latent variable modeling of the domains are displayed in S3 Fig.
In the sensitivity analysis, larger number of CAG repeats is associated with a faster decline
over time, in all domains except behavior. Met/Val HD gene carriers decline faster than Val/
Val HD gene carriers in motor domain. Met/Met HD gene carriers decline faster than Val/Val
and Met/Val HD gene carriers in cognitive domain, but the associated P-value is no longer sig-
nificant after Bonferroni correction (see S2 Table).
Table 3. Impact of COMT genotype and the number of CAG repeats in the long allele on disease evolution within the four domains.
Domains Motor (N = 348) Behavior (N = 348) Functional (N = 348) Cognitive (N = 344)
Estimate P Estimate P Estimate P Estimate P
(SE) (Corrected P) (SE) (Corrected P) (SE) (Corrected P) (SE) (Corrected P)
Baseline:
Met/Val vs Met/Met 0.08 0.6595 -0.39 0.1592 -0.10 0.5478 -0.30 0.0521
(0.18) (ns) (0.28) (ns) (0.17) (ns) (0.16) (ns)
Val/Val vs Met/Met -0.26 0.1825 -0.18 0.5427 -0.19 0.3105 -0.37 0.0344*
(0.20) (ns) (0.30) (ns) (0.19) (ns) (0.17) (ns)
Val/Val vs Met/Val -0.34 0.0383* 0.21 0.3708 -0.09 0.5654 -0.06 0.6605
(0.16) (ns) (0.23) (ns) (0.16) (ns) (0.15) (ns)
Number of CAG repeats -0.01 0.4087 0.07 0.1202 0.04 0.0391* 0.03 0.0443*
(0.02) (ns) (0.04) (ns) (0.02) (ns) (0.02) (ns)
Education level 0.04 0.0500 0.05 0.0181* 0.06 0.0014** 0.08 <0.0001***
(0.02) (ns) (0.02) (ns) (0.02) (0.0056**) (0.02) (0.0001***)
Gender Man vs Woman -0.04 0.7566 0.54 0.0082** 0.30 0.0233* -0.04 0.7436
(0.14) (ns) (0.20) (0.0328*) (0.13) (ns) (0.12) (ns)
Slope:
Met/Val vs Met/Met -0.01 0.3671 0.06 0.0171* 0.02 0.1339 0.04 <0.0001***
(0.01) (ns) (0.02) (ns) (0.01) (ns) (0.01) (<0.0001***)
Val/Val vs Met/Met 0.02 0.1160 0.03 0.2961 0.01 0.4642 0.03 0.0002***
(0.01) (ns) (0.03) (ns) (0.01) (ns) (0.01) (0.0012**)
Val/Val vs Met/Val 0.03 0.0044** -0.03 0.1711 -0.01 0.4700 -0.01 0.2221
(0.01) (0.0264*) (0.02) (ns) (0.01) (ns) (0.01) (ns)
Number of CAG repeats -0.01 <0.0001*** -0.01 0.0953 -0.01 <0.0001*** -0.01 <0.0001***
(0.001) (<0.0001) (0.004) (ns) (0.001) (<0.0001***) (0.001) (<0.0001***)
Gender Man vs Woman 0.03 0.0016** -0.06 0.0042** -0.01 0.3862 0.02 0.0020**
(0.01) (0.0064**) (0.02) (0.0168*) (0.01) (ns) (0.01) (0.0080**)
The motor domain was modeled including the performances at TMS; the behavioral domain was modeled including the performances at behavior task of
the UHDRS; the functional domain was modeled including the performances at FAS and IS (TFC could not be included because there are not enough
values for the model to converge); the cognitive domain was modeled including performances at letter fluency assessed at 1 and 2 minutes, SDMT and the
three parts of the Stroop.
N: Number of HD gene carriers who have contributed to the estimation (cognitive tasks were not available for all HD gene carriers); SE: Standard error of
the estimate
P: P-values (*** P<0.001, ** P<0.01, *P<0.05).
Baseline values correspond to the impact of covariates at estimated age at onset. Slope values correspond to the impact of covariates on the slope of the
decline.
doi:10.1371/journal.pone.0161106.t003
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Discussion
We investigated the impact of COMT polymorphism in a prospectivemulticentre study of 438
HD gene carriers at all stages of HD, from which 350, with identified age of onset, were fol-
lowed up once a year with the UHDRS during 4.8 (SD = 2.9) years. The COMT polymorphism
distribution in this sample is similar to that reported for the European population [39]. As pre-
viously reported, the number of CAG repeats affects the age at onset and the disease progres-
sion in our cohort [3, 9]. Higher educational level improves cognitive performance at baseline,
as observed in elderly populations [40]. We show that COMT polymorphism influences disease
progression in a biphasic way in the cognitive and motor domains, and tends to influence the
functional domain as well. Met/Met HD gene carriers outperformVal/Val HD gene carriers in
the cognitive during the first 10 years after disease onset. However, since the slope of decline is
steeper in the Met/Met HD gene carriers, they then performedworse than Val/Val HD gene
carriers. The effect of COMT polymorphism is of particular interest because, in contrast to
other genetic modulations previously reported, this polymorphism affects progression rather
than age at onset [2, 4].
Fig 3. Curves of the impact of COMT polymorphism on the motor, behavioral, functional and cognitive
domains, in a modeled cohort of a woman HD patients with 45 CAG repeats and 12-year education level.
We plotted the evolution of performance as a function of time for each task. Performance decrease was
represented by a negative slope. 45 CAG repeats is the mean number in the cohort studied. The latent motor
process was modeled using the UHDRS motor score; the latent behavioral process was modeled using the
UHDRS behavioral score; the latent functional process was modeled using the FAS and IS scores; The latent
cognitive process was modeled using letter fluency at 1 minute, letter fluency at 2 minutes, SDMT, Stroop Color,
Stroop Word and Stroop Word/Color interference.
doi:10.1371/journal.pone.0161106.g003
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This study replicates the effect of the number of CAG repeats observed in other studies [41,
42]. It allows deciphering the effect of COMT polymorphism presumably because unlike previ-
ous studies on other cohorts [43], we did not select HD gene carriers at particular disease stages
or with a specific number of CAG repeats. In addition we improved the value of our results by
selecting the number of CAG repeats without including the age at onset as a covariate despite
its known value [8] to avoid redundancy [44] since the age at onset and the number of CAG
repeats are two correlated factors [3, 33]. Furthermore, the use of a single language for cogni-
tive testing decreased inter-subject variability in cognitive performance. The HD gene carriers
were followed up prospectively for as long as possible, from pre-manifest to advanced stages.
Althoughmost of the data was collected between 5 and 15 years after disease onset, it provides
a unique continuum of disease progression with enough follow up data to conduct a longitudi-
nal analysis. Results of the sensitivity analysis displayed the same trend as the analysis of the
whole sample, however without reaching significance after Bonferroni correction for multiple
testing.
The latent-class mixed model has the advantage of grouping several tasks within domains
and provides a global picture by domain without focusing on specific tasks. This approach,
recently developed, is already used in studies evaluating cognitive decline [45, 46]. To ensure
that it models disease progression as well as the classical task by task multiple linear mixed
model [47, 48], we ran both latent-class mixed models and the linear mixed models on our
data (see S3 Table). Both models show higher cognitive decline for the Met/Met group. The
latent-mixed model has also the advantage of avoiding the calculation of sum of performance
for tasks with different weights and to take into account all assessments, and not only a delta
between baseline and last assessment, as in some regression linear analyses [49].
Our study shows that the impact of COMT polymorphism differs according to each domain
like in previous studies of Parkinson’s disease and schizophrenia [19, 20, 50]. The effect of
COMT polymorphismwas observed in the cognitive and motor domains but not in the behav-
ioral and functional domains. However, the pattern was similar in the motor, cognitive and
functional domains, without reaching significance in the latter. The Val/Val group show a less
steep progression than the Met/Met group in the cognitive domain, and than the Met/Val
group in the motor domain. The lack of significance in the functional domain presumably
relies on the smaller range of performance in this domain than in the motor and cognitive
domains. It is worth noting that in contrast, the behavioral score does not show any decline
overtime in HD.
The impact of COMT polymorphism on cognitive functions is of particular interest because
the cognitive abilities are the major cause of social withdrawal in HD. Executive functions are
modulated by COMT polymorphism, and improve along with the increase of DA availability,
as observed in healthy individuals with the Met/Met genotype [51]. DA in the striatum has
phasic variations and affects executive tasks requiring cognitive flexibility and switching
between object features, such as in theWisconsin Card Sorting Test and attention set-shifting
test [52]. In the PFC, DA availability is more tonic and modulates the ability to maintain infor-
mation as required in selective attention or working memory [53, 54]. The tasks we used here
fall into this latter category presumably taping the PFC.
Fig 4. Curves of the impact of COMT polymorphism on each UHDRS score, in a modeled cohort of a female HD patient with
45 CAG repeats and 12-year education level. We plotted the evolution of performance for each task. 45 CAG repeats is the mean
number in the cohort studied. UHDRS motor score (A); UHDRS behavioral (B), IS: Independence Score (C); FAS: Functional
Assessment Scale (D), cognitive (letter fluency 1’: at 1 minute (E); letter fluency 2’: at 2 minutes (F); SDMT: symbol digit modalities
test (G); Stroop C: Stroop color (H); Stroop W: Stroop word (I); Stroop W/C: Stroop interference (J).
doi:10.1371/journal.pone.0161106.g004
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These effects on disease progression have implications for our understanding of the dynam-
ics of DA in the PFC and striatum in HD. COMT influencesDA levels, mostly in the PFC, con-
sistent with the specific effect on cognitive symptoms observed in HD. Indeed, DA antagonists
with systemic action, which reduce DA levels in both the PFC and striatum, have been shown
to worsen cognitive impairment [27] and chorea intensity at early stages. As in healthy individ-
uals [22], the higher availability of DA in the Met/Met genotype is associated with a preserva-
tion of cognitive function at early stages. The greater availability of DA in Met/Met individuals
appears to have an effect similar to cognitive reserve in the initial stages of the disease. The
effects of high DA levels, which are initially beneficial in the early stages of the disease, eventu-
ally become detrimental, due to the long-term toxicity of DA in striatal cells [26].
This biphasic pattern over time suggests a symptomatic, rather than neuroprotective effect.
Consistently, early and chronic treatment with the D2 antagonist haloperidol decanoate pro-
tects against neuronal dysfunction and aggregate formation in a rat model of HD [55]. COMT
polymorphism also determines the response to entacapone [29] but not to levodopa. Consider-
ing the similar trend of evolution in the cognitive, motor and functional domains, we cannot
rule out the possibility of the Val allele being neuroprotective per se, since Met/Met individuals
Fig 5. Schematic representation of the biphasic effect of COMT polymorphism in HD. In the prefrontal
cortex, DA levels are higher in Met/Met HD gene carriers at early stages and in HD gene carriers with premanifest
disease than in controls. These levels subsequently decrease over time in both the Met/Met (in blue) and Val/Val
groups (in red) [56]. The high levels of DA present in the PFC at early stages result in better cognitive
performances. At late stages, higher levels of DA in the PFC in Met/Met HD gene carriers may be toxic, increasing
atrophy [26, 51]. In both COMT groups, the level of striatal DA decreases over time.
doi:10.1371/journal.pone.0161106.g005
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display greater gray matter degeneration within DA-innervated structures, including the stria-
tum [51].
These results open up new possibilities for treatments tailored to patient genotype, slowing
disease progression, especially for treatments controlling cognitive function decline, which are
currently lacking. It should pave the way for personalized treatment in HD gene carriers by
adapting treatment to time- and region-specific changes, takingCOMT genotype into account.
At early stages of the disease, the combination of treatments decreasingDA levels in the stria-
tum and COMT inhibitors increasing DA levels in the PFC, might prevent the exacerbation of
cognitive deficits, or even improve cognitive ability (Fig 5) in Val/Val HD gene carriers. It has
an immediate application in pharmacologicalmanagement of HD, as inhibitors or activators
of COMT are already available. At later stages, more than 10 years after onset, it may be harder
to target DA levels in the PFC specifically, as classical antipsychotic drugs occupy a large pro-
portion of subcortical dopamine D2 receptors, whereas atypical antipsychotics preferentially
occupy cortical 5-HT(2) receptors.
Our study also has practical implications for future clinical trials assessing decline in HD
becauseCOMT polymorphism appears as an important factor of stratification.Moreover, the
methodologywe used could be adapted to other neurodegenerative diseases.
Supporting Information
S1 Fig. Distribution of CAG repeats length in the database.
(TIF)
S2 Fig. Repartition of stages in time according to COMT polymorphisms.
(TIF)
S3 Fig. Link functions between performances at each task and latent processesmodelling
the domains.We plotted the link function between each task and latent domains. UHDRS
motor score (A); UHDRS behavioral (B), IS: Independence Score (C); FAS: Functional Assess-
ment Scale (D), cognitive (letter fluency 1’: at 1 minute (E); letter fluency 2’: at 2 minutes (F);
SDMT: symbol digit modalities test (G); Stroop C: Stroop color (H); StroopW: Stroop word
(I); StroopW/C: Stroop interference (J).
(TIF)
S1 Table. Demographic characteristics and performance of HD gene carriers including in
the longitudinal analysis (N = 350).HD: Huntington’s disease; BMI: bodymass index; CAG
repeats refers to the number of CAGs in the mutated (mHtt) and non-mutated (normalHtt)
alleles of the Huntingtin gene; UHDRS: Unified Huntington’s Disease Rating Scale; TMS:
Total Motor Score; FAS: Functional Assessment Scale; IS: Independence Scale; TFC: Total
Functional Capacity; Letter fluency (L Fluency) was tested with PRV letters (French norms) at
1 minute (1’) and 2 minutes (2’); Stroop C: Color;W: Word; W/C:Word/Color (interference
score); SDMT: Symbol Digit Modalities Test. Quantitative variables are presented as means,
with the standard deviation in brackets, and qualitative variables are presented as frequency
counts. Medication use is expressed as a percentage.Non correctedP-values; Chi-squared test
for qualitative variables and one-way ANOVA for quantitative data; Ns: not significant.
(DOCX)
S2 Table. Modelling results of the sensitivity analysis excluding outliers.The motor domain
was modeled including the performances in the TMS; the behavioral domain was modeled
including the performances at behavior task of the UHDRS; the functional domain was mod-
eled including the performances at FAS and IS (TFC could not be included because there are
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not enough values for the model to converge); the cognitive domain was modeled including
performances at letter fluency assessed at 1 and 2 minutes, SDMT and the three parts of the
Stroop. N: Number of HD gene carriers who have contributed to the estimation (cognitive
tasks were not available for all HD gene carriers); SE: Standard error of the estimate, P: P-values
( P<0.001,  P<0.01, P<0.05). Baseline values correspond to the impact of covariates at
estimated age at onset. Slope values correspond to the impact of covariates on the slope of the
decline.
(DOCX)
S3 Table. Modelling results of linearmixedmodels for each tasks. TMS: Total motor score,
IS: Independence Scale, FAS: Functional Assessment Scale, SDMT: Symbol Digit Modalities
Test, Stroop C: Stroop Color, StroopW: StroopWord, StroopW/C: Stroop interference. N:
Number of HD gene carriers who have contributed to the estimation (cognitive tasks were not
available for all HD gene carriers); SE: Standard error of the estimate, P: P-values ( P<0.001,
 P<0.01, P<0.05). Baseline values correspond to the impact of covariates at estimated age at
onset. Slope values correspond to the impact of covariates on the slope of the decline.
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